

Cáncer de cervix¹

Base de Datos Medline. Búsqueda hasta Marzo 2005, artículos de revisión (review papers).

16264881

1. Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. *Nat Clin Pract Oncol* 2005;2(2):90-7.
2. Lau S, Franco EL. Management of low-grade cervical lesions in young women. *CMAJ* 2005;173(7):771-4.
3. Buechler EJ. Pap tests and HPV infection. Advances in screening and interpretation. *Postgrad Med* 2005;118(2):37-40, 43-6.
4. Pappa KI, Anagnostou NP. Emerging issues of the expression profiling technologies for the study of gynecologic cancer. *Am J Obstet Gynecol* 2005;193(3 Pt 2):908-18.
5. Denny L. The prevention of cervical cancer in developing countries. *BJOG* 2005;112(9):1204-12.
6. Bundrick JB, Cook DA, Gostout BS. Screening for cervical cancer and initial treatment of patients with abnormal results from papanicolaou testing. *Mayo Clin Proc* 2005;80(8):1063-8.
7. Hellberg D, Stendahl U. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. *Anticancer Res* 2005;25(4):3041-6.
8. El-Ghobashy AA, Shaaban AM, Herod J, Herrington CS. The pathology and management of endocervical glandular neoplasia. *Int J Gynecol Cancer* 2005;15(4):583-92.
9. Narayan K. Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer. *Int J Gynecol Cancer* 2005;15(4):573-82.
10. Sheary B, Dayan L. Cervical screening and human papillomavirus. *Aust Fam Physician* 2005;34(7):578-80.
11. Holland CM, Shafi MI. Radical hysterectomy. *Best Pract Res Clin Obstet Gynaecol* 2005;19(3):387-401.
12. Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic cervical human papillomavirus infection. *Infect Dis Clin North Am* 2005;19(2):439-58.
13. Serkies K, Jassem J. Chemotherapy in the primary treatment of cervical carcinoma. *Crit Rev Oncol Hematol* 2005;54(3):197-208.
14. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. *Lancet Oncol* 2005;6(5):328-33.
15. Brink AA, Zielinski GD, Steenbergen RD, Snijders PJ, Meijer CJ. Clinical relevance of human papillomavirus testing in cytopathology. *Cytopathology* 2005;16(1):7-12.
16. Chirenje ZM. HIV and cancer of the cervix. *Best Pract Res Clin Obstet Gynaecol* 2005;19(2):269-76.
17. Willis BH, Barton P, Pearmain P, Bryan S, Hyde C. Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. *Health Technol Assess* 2005;9(13):1-207, iii.
18. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. *Vaccine* 2005;23(17-18):2388-94.
19. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. *J Clin Virol* 2005;32 Suppl 1:S16-24.
20. Waxman AG. Guidelines for cervical cancer screening: history and scientific rationale. *Clin Obstet Gynecol* 2005;48(1):77-97.
21. Moscicki AB. Human papilloma virus, papanicolaou smears, and the college female. *Pediatr Clin North Am* 2005;52(1):163-77, ix.
22. Muggia FM. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. *Semin Oncol* 2004;31(6 Suppl 14):17-24.
23. De Los Santos JF, Small W. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions. *Semin Oncol* 2004;31(6 Suppl 18):37-41.

1. En colaboración con la Biblioteca Médica Nacional, UNAH (<http://cidbimena.desastres.hn>), y el Comité Consultivo de la Biblioteca Virtual en Salud de Honduras (<http://www.bvs.hn>).

24. Padilla-Paz LA. Emerging technology in cervical cancer screening: status of molecular markers. *Clin Obstet Gynecol* 2005;48(1):218-25.
25. Parker MF. Emerging technology in cervical cancer screening: spectroscopy. *Clin Obstet Gynecol* 2005;48(1):209-17.
26. Bidus MA, Elkas JC, Rodriguez M, Maxwell GL, Rose GS. The clinical utility of the diagnostic endocervical curettage. *Clin Obstet Gynecol* 2005;48(1):202-8.
27. Dainty LA, Elkas JC, Rose GS, Zahn CM. Controversial topics in abnormal cervical cytology: "see and treat". *Clin Obstet Gynecol* 2005;48(1):193-201.
28. Brown D, Berran P, Kaplan KJ, Winter WE 3rd, Zahn CM. Special situations: abnormal cervical cytology during pregnancy. *Clin Obstet Gynecol* 2005;48(1):178-85.
29. Cox JT. Management of women with cervical cytology interpreted as ASC-US or as ASC-H. *Clin Obstet Gynecol* 2005;48(1):160-77.
30. Soto-Wright V, Samuelson R, McLellan R. Current management of low-grade squamous intraepithelial lesion, high-grade squamous epithelial lesion, and atypical glandular cells. *Clin Obstet Gynecol* 2005;48(1):147-59.
31. Farley J, McBroom JW, Zahn CM. Current techniques for the evaluation of abnormal cervical cytology. *Clin Obstet Gynecol* 2005;48(1):133-46.
32. Bidus MA, Zahn CM, Maxwell GL, Rodriguez M, Elkas JC, Rose GS. The role of self-collection devices for cytology and human papillomavirus DNA testing in cervical cancer screening. *Clin Obstet Gynecol* 2005;48(1):127-32.
33. Russell J, Crothers BA, Kaplan KJ, Zahn CM. Current cervical screening technology considerations: liquid-based cytology and automated screening. *Clin Obstet Gynecol* 2005;48(1):108-19.
34. Waxman AG. Guidelines for cervical cancer screening: history and scientific rationale. *Clin Obstet Gynecol* 2005;48(1):77-97.
35. Fox H. Ploidy in gynaecological cancers. *Histopathology* 2005;46(2):121-9.
36. Smith I. Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. *Oncology (Huntingt)* 2004;18(13 Suppl 8):63-5.
37. Tomson TT, Roden RB, Wu TC. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. *Curr Opin Investig Drugs* 2004;5(12):1247-61.
38. Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. *Recent Results Cancer Res* 2005;166:277-97.
39. Cardenas-Turan M, Follen M, Benedet JL, Cantor SB. See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions. *Lancet Oncol* 2005;6(1):43-50.
40. Bartholomew DA. Human papillomavirus infection in adolescents: a rational approach. *Adolesc Med Clin* 2004;15(3):569-95.
41. Loerzel VW, Bushy A. Interventions that address cancer health disparities in women. *Fam Community Health* 2005;28(1):79-89.
42. Perez CA. Dose fractionation and biological optimization in carcinoma of the uterine cervix. *Rays* 2004;29(3):253-70.
43. Jansen KU. Toward vaccines against cervical cancer. *Curr Opin Drug Discov Devel* 2004;7(2):228-32.
44. Baay MF, Weyler J, Vermorken JB. The value of human papillomavirus detection in primary cervical cancer screening. *Eur J Gynaecol Oncol* 2004;25(6):665-9.
45. Ramirez PT, Frumovitz M, Wolf JK, Levenback C. Laparoscopic port-site metastases in patients with gynecological malignancies. *Int J Gynecol Cancer* 2004;14(6):1070-7.
46. Apgar BS, Brotzman G. Management of cervical cytologic abnormalities. *Am Fam Physician* 2004;70(10):1905-16.
47. Papadia A, Remorgida V, Salom EM, Ragni N. Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic oncology. *J Am Assoc Gynecol Laparosc* 2004;11(3):297-306.
48. Dunleavy R. Incidence, pathophysiology and treatment of cervical cancer. *Nurs Times* 2004;100(44):38-41.
49. Bertram CC. Evidence for practice: oral contraception and risk of cervical cancer. *J Am Acad Nurse Pract* 2004;16(10):455-61.
50. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. Mechanisms of human papillomavirus-induced oncogenesis. *J Virol* 2004;78(21):11451-60.
51. Kahn JA, Hillard PA. Human papillomavirus and cervical cytology in adolescents. *Adolesc Med Clin* 2004;15(2):301-21, ix.
52. Ledwaba T, Dlamini Z, Naicker S, Bhoola K. Molecular genetics of human cervical cancer: role of

- papillomavirus and the apoptotic cascade. *Biol Chem* 2004; 385(8):671-82.
53. Green AE, Biscotti C, Michener C, Belinson J. Isolated cervical metastasis of breast cancer: a case report and review of the literature. *Gynecol Oncol* 2004; 95(1):267-9.
 54. Anhang R, Goodman A, Goldie SJ. HPV communication: review of existing research and recommendations for patient education. *CA Cancer J Clin* 2004;54(5):248-59.
 55. Kaplan KJ, Dainty LA, Dolinsky B, Rose GS, Carlson J, McHale M, Elkas JC. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. *Cancer* 2004;102(4):228-32.
 56. Tjalma WA, Arbyn M, Paavonen J, van Waes TR, Bogers JJ. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. *Int J Gynecol Cancer* 2004;14(5):751-61.
 57. Singh N, Arif S. Histopathologic parameters of prognosis in cervical cancer--a review. *Int J Gynecol Cancer* 2004;14(5):741-50.
 58. Storck K, Crispens M, Brader K. Squamous cell carcinoma of the cervix presenting as lymphangitic carcinomatosis: a case report and review of the literature. *Gynecol Oncol* 2004;94(3):825-8.
 59. Tan GC, Isa MR, Ng SP, Jamil YM. Unusual form of superficial spreading microinvasive squamous cell carcinoma of uterine cervix involving the endometrium of uterus. *J Obstet Gynaecol Res* 2004;30(5):363-7.
 60. Haverkos HW. Viruses, chemicals and co-carcinogenesis. *Oncogene* 2004; 23(38):6492-9.
 61. Stead ML. Sexual function after treatment for gynecological malignancy. *Curr Opin Oncol* 2004;16(5):492-5.
 62. Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. *Curr Opin Oncol* 2004;16(5):485-91.
 63. Ahamad A, Jhingran A. New radiation techniques in gynecological cancer. *Int J Gynecol Cancer* 2004;14(4):569-79.
 64. Shinn SE. Taking a stand against cervical cancer. *Nursing* 2004;34(5):36-41.
 65. Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. *Hum Pathol* 2004;35(8):971-82.
 66. Gray SH, Walzer TB. New strategies for cervical cancer screening in adolescents. *Curr Opin Pediat* 2004;16(4):344-9.
 67. Wani K, Nair CK. Genetic alterations in cervical cancer. *Indian J Exp Biol* 2003; 41(8):789-96.
 68. Carr KC, Sellors JW. Cervical cancer screening in low resource settings using visual inspection with acetic acid. *J Midwifery Womens Health* 2004;49(4):329-37.
 69. Ellenson LH, Wu TC. Focus on endometrial and cervical cancer. *Cancer Cell* 2004; 5(6):533-8.
 70. Scott A, Glasier AF. Are routine breast and pelvic examinations necessary for women starting combined oral contraception? *Hum Reprod Update* 2004;10(5):449-52.
 71. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. *Microbiol Mol Biol Rev* 2004;68(2):362-72.
 72. Chang AR. The pivotal role of the pathology laboratory in the context of a Singapore cervical cancer screening programme. *Singapore Med J* 2004;45(6):257-66.
 73. Torne A, Puig-Tintore LM. The use of sentinel lymph nodes in gynaecological malignancies. *Curr Opin Obstet Gynecol* 2004;16(1):57-64.
 74. Moodley J. Combined oral contraceptives and cervical cancer. *Curr Opin Obstet Gynecol* 2004;16(1):27-9.
 75. Reynolds D. Cervical cancer in Hispanic/Latino women. *Clin J Oncol Nurs* 2004;8(2):146-50.
 76. Trinh XB, Bogers JJ, Van Marck EA, Tjalma WA. Treatment policy of neuroendocrine small cell cancer of the cervix. *Eur J Gynaecol Oncol* 2004;25(1):40-4.
 77. Tristram A, Fiander A. Vaccination against cervical cancer. *Hosp Med* 2004; 65(3):160-3.
 78. Bekkers RL, Massuger LF, Bulten J, Melchers WJ. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. *Rev Med Virol* 2004;14(2):95-105.
 79. Schorge JO, Knowles LM, Lea JS. Adenocarcinoma of the cervix. *Curr Treat Options Oncol.* 2004 Apr;5(2):119-27.
 80. Renshaw AA. Increased cervical cancer screening intervals: a risky investment? *Diagn Cytopathol* 2004;30(3):137-8.
 81. Cronje HS. Screening for cervical cancer in developing countries. *Int J Gynaecol Obstet* 2004;84(2):101-8.
 82. Utsugi K, Shimizu Y, Akiyama F, Umezawa S, Hasumi K. Clinicopathologic features of villoglandular papillary adenocarcinoma of the uterine cervix. *Gynecol Oncol*

- 2004;92(1):64-70.
83. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. *Int J Cancer* 2004;109(2):157-62.
 84. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. *Annu Rev Med* 2004;55:319-31.
 85. Lazcano-Ponce E, Alonso P, Ruiz-Moreno JA, Hernandez-Avila M. Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development. *Salud Publica Mex* 2003;45 Suppl 3:S449-62.
 86. Villa LL. Vaccines against papillomavirus infections and disease. *Salud Publica Mex* 2003;45 Suppl 3:S443-8.
 87. Garcia-Carranca A. Vaccines against human papillomavirus and perspectives for the prevention and control of cervical cancer. *Salud Publica Mex* 2003;45 Suppl 3:S437-42.
 88. Franceschi S, Clifford G, Plummer M. Prospects for primary prevention of cervical cancer in developing countries. *Salud Publica Mex*. 2003;45 Suppl 3:S430-6.
4. Claros Sabillón JM. Cáncer de cuello uterino estado clínico III: Análisis retrospectivo de su manejo y resultados. *Rev Med Hondur* 1983; 51(2):45-53.
 5. Moradel MA, Crespin Beltrán MA, Aguilar O. Conización del cuello uterino en patología cervical. *Rev Med Hondur* 1992; 60(4):163-6.
 6. Samayoa Moncada E, López Canales JR, Romero Roveló A. Crioterapia en el tratamiento de las neoplasias intraepiteliales cervicales. *Rev Med Hondur* 1992; 60(2):58-63.
 7. Raudales Barahona O. Declina el carcinoma del cuello uterino en San Pedro Sula. *Rev Med Hondur* 1992;60(3):143-5.
 8. Flores Funes OR, Maldonado MJ, Arita JL. Cáncer asociado con embarazo. *Rev Med Hondur* 1991;59(2):67-8-73.
 9. Alvarado D. Lesiones premalignas de cervix y su relación con virus papiloma humano. *Rev Med Hondur* 1988;56(1):62-7.
 10. Moradel MA, Murillo F. Criocirugía en el tratamiento de la neoplasia intraepitelial cervical. *Rev Med Hondur* 1988;56(1):4-11.
 11. Moradel MA. Correlación histológica, citológica y colposcópica en detección precoz de la patología cervical. *Rev Med Hondur* 1984;52(4):205-9.
 12. Medina C, Mendoza JE. Cáncer de cuello uterino en prolapso uterino. *Rev Med Hondur* 1976; 4(44):195-202.
 13. Faraj E. Análisis estadístico de los resultados obtenidos en la clínica Detectora del Cáncer Cérvico-Uterino de Tegucigalpa, 1960-62. *Rev Med Hondur* 1963; 31(3): 4-18.

SITIOS WEB

1. <http://www.cdc.gov/cancer/nbccedp/info-cc.htm>
2. <http://www.cancer.gov/cancertopics/types/cervical>
3. <http://www.alliance-cxca.org/>
4. http://www.who.int/reproductive-health/cancers/cervical_cancer_screening_in_dev_countries.pdf
5. <http://www.paho.org/English/AD/DPC/NC/pcc-cc-sit-lac.htm>

REVISTA MEDICA HONDUREÑA

1. Sosa Montiel M, Rivera López R. Importancia de la citología vaginal (Papanicolau): para detectar cáncer cérvico uterino en mujeres mayores de 15 años a nivel de una Clínica privada. *Rev Med Hondur* 2000; 68(3):86-8.
 2. Flores Funes OR, Cárcamo Mejía JA. Cáncer cervicouterino en prolapso. *Rev Med Hondur* 1993; 61(3):104-8.
 3. Samayoa E. Evaluación de las lesiones precancerosas del cérvix uterino, uso de la crioterapia o el cono. *Rev Med Hondur* 1993; 61(3):84-90.
1. Chavarría Chinchilla A, Arita Erazo J. Características demográficas de las mujeres embarazadas con neoplasmas de cervix controladas en la Consulta Externa del Materno Infantil de Honduras. *Rev Med Post UNAH* 2002; 7: 190-195.
 2. Honduras. Secretaría de Salud. Programa Nacional para el Control del Cáncer. Manual de normas y procedimientos para la prevención y control del cáncer cérvico uterino Tegucigalpa; OPS; FNUAP; dic. 1997.
 3. Honduras. Secretaría de Salud Pública. Cáncer cervicouterino, manual de normas y procedimientos. Honduras, Secretaría de Salud Pública; 1989.

OTRAS REVISTAS Y DOCUMENTOS

TESIS PARA OPTAR AL GRADO DE DOCTOR EN MEDICINA

1. Taylor ML. Estudio del comportamiento del cáncer de cérvix estadio IIIb en pacientes manejadas en el Hospital San Felipe, durante el período 1981-1982. HN1.1/616.99466*T24e, 1989.
2. Barillas TI, García Sorto E. Análisis del tratamiento del cáncer de cérvix en estadio clínico II en el Hospital General San Felipe en el período 1983-1986. HN1.1/616.99466*B25, 1989.
3. Gallardo Barrios JA. Conización en el diagnóstico de cáncer de cérvix. Revisión de 200 Casos, Hospital Escuela, Tegucigalpa. HN1.1/616.99266*G16, 1985.
4. Hepburn Greenberg JA. Conización en diagnóstico de cáncer de cérvix, 1982 a 1986, Hospital Leonardo Martínez Valenzuela. HN1.1/616.99214*H52, 1987.
5. Valerio Centeno VM. Influencia de las infecciones del aparato genital femenino, en el diagnóstico y tratamiento del cáncer de cérvix uterino en el Departamento de Oncología del Hospital General San Felipe, de Agosto de 1987 a Octubre de 1987. HN1.1/616.99266*V15, 1988.
6. Silva Zerón CY. Detección citológica de cáncer de cérvix en el CESAMO de Catacamas, Olancho. Período Enero 1981 a Octubre 1985. HN1.1/616.99266*S58, 1986.

